Microdosing psychedelics, or ingesting extremely tiny sub-perceptual amounts of drugs like psilocybin or LSD, has lately become more fashionable in recent years.
Benefits based on supporters range from enhanced creativity and mood to decreased anxiety and sadness.
Why It’s Gaining Attention
In controlled clinical trials, psychedelic-assisted therapy (at maximum therapeutic doses) has demonstrated encouraging outcomes for end-of-life anxiety, despair, and PTSD. This has increased curiosity about whether microdoses could be beneficial without causing hallucinations or strong psychological impacts.
Some users report:
-
Improved focus
-
Reduced depressive symptoms
-
Enhanced emotional resilience
However, most evidence remains observational or self-reported.
The Scientific Gap
Unlike full-dose psychedelic therapy conducted under supervision, microdosing:
-
Lacks large-scale randomized controlled trials
-
Has inconsistent dosing standards
-
Faces regulatory restrictions
-
May carry unknown long-term risks
Placebo-controlled studies have produced mixed results, with some suggesting expectancy effects may play a significant role.
The Bigger Question
We may be witnessing a shift in psychiatric drug development from daily SSRIs toward episodic or receptor-targeted interventions involving serotonin pathways in novel ways.
But before normalization, rigorous evidence is essential.
Should official clinical research on microdosing psychedelics be expedited, or should caution be maintained until more solid controlled evidence is obtained?
MBH/AB